IHH and neoplasm: In contrast, treatment of KrasLSL-G12D/+; Trp53fl/fl mice with the anti-SHH/IHH blocking antibody, 5E1 [175], early in the tumorigenic process caused increased tumor burden and metastasis, an increase in poorly differentiated tumor histology, and worse survival.